Key Segments
By Treatment Type
- Hormonal Therapies
- Estrogen-based Therapies
- Progestin-based Therapies
- Combination Therapies
- Non-Hormonal Therapies
- Neurokinin-3 (NK3) Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Gabapentinoids
- Phytoestrogens & Herbal Products
- Others (Cognitive Behavioral Therapy (CBT), Lifestyle & Dietary Supplements)
By Route of Administration
- Oral
- Topical/Transdermal
- Vaginal
- Parenteral
By Formulation Type
- Tablets/Capsules
- Creams/Gels
- Patches
- Vaginal Rings & Pessaries
- Injections
- Others (Oral Dissolving Films, and Extended-release Pellets)
By Indication
- Perimenopause
- Menopause
- Postmenopause
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics & Stores
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Safety concerns with hormone replacement therapy (HRT) and limited awareness in emerging markets are major challenges.
Ans: The growing incidence of menopause-related health issues and rising adoption of hormonal and non-hormonal therapies are key growth drivers.
Ans: North America dominates the market, led by the U.S., due to high healthcare spending and the availability of FDA-approved therapies.
Ans: The market is expected to grow at a CAGR of 5.44% from 2025 to 2032, fueled by increasing hormonal imbalance issues and aging populations.
Ans: The global menopause treatment market was valued at USD 17.84 billion in 2024, driven by rising awareness and treatment demand.